Gen İlaç Signs 5-Year Exclusive Agreement with Pfizer

Gen İlaç has signed a five-year exclusive sales, marketing, and distribution agreement with global pharmaceutical giant Pfizer. This strategic partnership aims to enhance the value of products in Gen İlaç's portfolio. Under the agreement, Gen İlaç will undertake the sales and distribution of certain Pfizer products in Turkey. This collaboration will allow Gen İlaç to expand its market share and benefit from operational economies of scale. The agreement with an established brand like Pfizer is expected to strengthen Gen İlaç's position in the industry while positively impacting the company's financial performance. The five-year term will support the company's growth potential by providing a long-term revenue stream. This is not investment advice.

📊 PFE — Piyasa Yorumu

▲ up · 60%

The news signals a positive partnership for Pfizer, which could have a short-term supportive effect on the stock. Technical indicators present a neutral-to-positive picture: RSI at 54 is balanced, while MACD is hovering near its signal line. The price has closed above the 20- and 50-day moving averages, indicating short-term upside potential. However, the MACD has not yet clearly crossed above the signal line, and the lack of volume data suggests that the rally may be limited. Therefore, a cautious uptrend can be expected.

RSI 14

54.9

MACD

0.07

24h Δ

1.05%

Canlı Grafikler